KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

James Bussel, Barbara Stegmann, Pamela Baker, Abbie Oey, Yanxin Jiang, Rebecca Zaha, Hillary Van Valkenburgh, Babajide Keshinro

Am J Perinatol 43(10) 1335-1344

PMID41290206
PMCIDPMC13345697
DOI10.1055/a-2753-9323
发表日期2025-11-25
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:研究设计图。
摘要

摘要

OBJECTIVE: Nipocalimab, a neonatal Fc receptor blocker, showed evidence of efficacy and safety in preventing or delaying fetal anemia in a phase 2 study of early-onset severe hemolytic disease of the fetus and newborn, demonstrating potential for treatment of other maternal immunoglobulin G alloantibody-mediated fetal diseases. The phase 3 FREESIA-3 study aims to evaluate the efficacy and safety of nipocalimab or intravenous immunoglobulin (IVIG) with prednisone in pregnancies with a previous occurrence of fetal and neonatal alloimmune thrombocytopenia (FNAIT) with or without intracranial hemorrhage or severe fetal/neonatal bleeding (high- or standard-risk, respectively). STUDY DESIGN: FREESIA-3 is a phase 3, open-label, randomized, multicenter study in pregnant individuals at risk for FNAIT. Participants are randomized 4:1 to receive either weekly 45 mg/kg intravenous nipocalimab or weekly IVIG with prednisone starting at 13 to 18 weeks of gestational age (standard-risk) or 12 weeks of gestational age (high-risk) until delivery. During treatment, pregnant participants will receive ultrasound monitoring every 2 weeks for fetal bleeding, growth, and development. Postnatal follow-up is 24 weeks for maternal participants and 104 weeks for neonates/infants. RESULTS: The primary endpoint is an adverse outcome of death or adjudicated severe bleeding in utero up to 1 week postbirth, or platelet count at birth of < 30 × 109/L in a fetus/neonate. Secondary endpoints include fetal/neonatal death, neonatal platelet count at birth, nadir neonatal platelet count over 1 week postbirth, neonate requiring platelet transfusion(s), adjudicated fetal and neonatal bleeding up to 1 week postbirth, neonate receiving IVIG for thrombocytopenia, safety in maternal participants and neonates/infants, and immunogenicity of nipocalimab. Exploratory endpoints include patient- and caregiver-reported outcome assessments and nipocalimab pharmacokinetics and pharmacodynamics. CONCLUSION: FREESIA-3, an open-label, multicenter, randomized, phase 3 study, will evaluate the efficacy and safety of nipocalimab in both standard- and high-risk pregnancies for FNAIT. KEY POINTS: · FNAIT is a transplacental alloantibody-driven disease.. · Nipocalimab blocks IgG recycling, lowering IgG levels.. · Nipocalimab blocks IgG placental transfer to the fetus.. · Nipocalimab reduced adverse outcomes in EOS-HDFN.. · FREESIA-3 studies nipocalimab efficacy/safety in FNAIT..

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Anticipated prevention of FNAIT by nipocalimab through ( A ) blocking transplacental transfer and ( B ) IgG recycling in maternal circulation. FcRn, neonatal Fc receptor; FNAIT, fetal and neonatal alloimmune thrombocytopenia; HPA, human platelet antigen; ICH, intracranial hemorrhage; IgG, immunoglobulin G. Reproduced with permission from Massachusetts Medical Society.
非 KM Figure
Fig. 2Fig. 2 FREESIA-3 study design. FNAIT, fetal and neonatal alloimmune thrombocytopenia; GA, gestational age; HPA, human platelet antigen; IV, intravenous; IVIG, intravenous immunoglobulin; QW, weekly; R, randomization. a Standard-risk: neonatal platelet count < 150 × 10 9 /L with no fetal/neonatal ICH or severe hemorrhage. High-risk: fetus/neonate with a history of ICH or severe hemorrhage in a previous child. b Delivery is planned to occur at 38 weeks, but may occur earlier at the discretion of the investigator and the study participant. c IVIG + prednisone dose regimen can be found in Table 2 .
非 KM Figure